<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1704221945
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tadafect
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        116.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit VII" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit VII
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QG04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Tadafect is a treatment for adult men with erectile dysfunction. This is when<br />a man cannot get, or keep a hard, erect penis suitable for sexual activity.<br />Tadafect has been shown to significantly improve the ability of obtaining a<br />hard erect penis suitable for sexual activity.<br />Tadafect contains the active substance tadalafil which belongs to a group<br />of medicines called phosphodiesterase type 5 inhibitors. Following sexual<br />stimulation Tadafect works by helping the blood vessels in your penis to relax,<br />allowing the flow of blood into your penis. The result of this is improved erectile<br />function. Tadafect will not help you if you do not have erectile dysfunction.<br />It is important to note that Tadafect does not work if there is no sexual<br />stimulation. You and your partner will need to engage in foreplay, just as<br />you would if you were not taking a medicine for erectile dysfunction.</p><p dir="ltr">It is important to note that Tadafect does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Tadafect if you:</strong><br />- are allergic to tadalafil or any of the other ingredients of this medicine<br />(listed in section 6).<br />- are taking any form of organic nitrate or nitric oxide donors such as<br />amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the<br />treatment of angina pectoris (&ldquo;chest pain&rdquo;). Tadafect has been shown to<br />increase the effects of these medicines. If you are taking any form of<br />nitrate or are unsure tell your doctor.<br />- have serious heart disease or recently had a heart attack within the last<br />90 days.<br />- recently had a stroke within the last 6 months.<br />- have low blood pressure or uncontrolled high blood pressure.<br />- ever had loss of vision because of non-arteritic anterior ischemic optic<br />neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.<br />- are taking riociguat. This drug is used to treat pulmonary arterial<br />hypertension (i.e., high blood pressure in the lungs) and chronic<br />thromboembolic pulmonary hypertension (i.e., high blood pressure in<br />the lungs secondary to blood clots). PDE5 inhibitors, such as Tadafect,<br />have been shown to increase the hypotensive effects of this medicine. If<br />you are taking riociguat or are unsure tell your doctor.</p><p dir="ltr"><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Tadafect.<br />Be aware that sexual activity carries a possible risk to patients with heart<br />disease because it puts an extra strain on your heart. If you have a heart<br />problem you should tell your doctor.<br />Before taking the tablets, tell your doctor if you have:<br />- sickle cell anaemia (an abnormality of red blood cells).<br />- multiple myeloma (cancer of the bone marrow).<br />- leukaemia (cancer of the blood cells).<br />- any deformation of your penis.<br />- a serious liver problem.<br />- a severe kidney problem.<br />It is not known if Tadafect is effective in patients who have had:<br />- pelvic surgery.<br />- removal of all or part of the prostate gland in which nerves of the<br />prostate are cut (radical non-nerve-sparing prostatectomy).<br />If you experience sudden decrease or loss of vision, stop taking Tadafect and<br />contact your doctor immediately.<br />Decreased or sudden hearing loss has been noted in some patients taking<br />tadalafil. Although it is not known if the event is directly related to tadalafil,<br />if you experience decreased or sudden hearing loss, stop taking Tadafect<br />and contact your doctor immediately.<br />Tadafect is not intended for use by women.<br /><strong>Children and adolescents</strong><br />Tadafect is not intended for use by children and adolescents under the age<br />of 18.</p><p dir="ltr"><strong>Other medicines and Tadafect</strong><br />Tell your doctor if you are taking, have recently taken or might take any<br />other medicines<br />Do not take Tadafect if you are already taking nitrates.<br />Some medicines may be affected by Tadafect or they may affect how well<br />Tadafect will work. Tell your doctor or pharmacist if you are already taking:<br />- an alpha blocker (used to treat high blood pressure or urinary<br />symptoms associated with benign prostatic hyperplasia).<br />- other medicines to treat high blood pressure.<br />- riociguat.<br />- a 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).<br />- medicines such as ketoconazole tablets (to treat fungal infections) and<br />protease inhibitors for treatment of AIDS or HIV infection.<br />- phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).<br />- rifampicin, erythromycin, clarithromycin or itraconazole.<br />- other treatments for erectile dysfunction.<br /><strong>Tadafect with drink and alcohol</strong><br />Information on the effect of alcohol is in section 3. Grapefruit juice may<br />affect how well Tadafect will work and should be taken with caution. Talk to<br />your doctor for further information.<br /><strong>Fertility</strong><br />When dogs were treated there was reduced sperm development in the<br />testes. A reduction in sperm was seen in some men. These effects are<br />unlikely to lead to a lack of fertility.<br /><strong>Driving and using machines</strong><br />Some men taking Tadafect in clinical studies have reported dizziness.<br />Check carefully how you react to the tablets before driving or using machines.<br /><strong>Tadafect contains lactose:</strong><br />If you have an intolerance to some sugars, contact your doctor before<br />taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Tadafect tablets are for oral use in men only. Swallow the tablet whole with<br />some water. The tablets can be taken with or without food.<br /><strong>The recommended starting dose </strong>is one 10 mg Tadalafil tablet before<br />sexual activity. However, you have been given the dose of one 20mg tablet</p><p dir="ltr">as your doctor has decided that the recommended dose of 10mg is too weak.<br />You may take a Tadafect tablet at least 30 minutes before sexual activity.<br />Tadafect may still be effective up to 36 hours after taking the tablet.<br />Do not take Tadafect more than once a day. Tadafect 20 mg is intended for<br />use prior to anticipated sexual activity and is not recommended for<br />continuous daily use.<br />It is important to note that Tadafect does not work if there is no sexual<br />stimulation. You and your partner will need to engage in foreplay, just as<br />you would if you were not taking a medicine for erectile dysfunction.<br />Drinking alcohol may affect your ability to get an erection and may<br />temporarily lower your blood pressure. If you have taken or are planning to<br />take Tadafect, avoid excessive drinking (blood alcohol level of 0.08 % or<br />greater), since this may increase the risk of dizziness when standing up.<br /><strong>If you take more Tadafect than you should</strong><br />Contact your doctor. You may experience side effects described in section 4.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not<br />everybody gets them. These effects are normally mild to moderate in nature.<br /><strong>If you experience any of the following side effects stop using the<br />medicine and seek medical help immediately:</strong><br />- allergic reactions including rashes (frequency uncommon).<br />- chest pain - do not use nitrates but seek immediate medical assistance<br />(frequency uncommon).<br />- priapsim, a prolonged and possibly painful erection after taking<br />Tadafect (frequency rare). If you have such an erection, which lasts<br />continuously for more than 4 hours you should contact a doctor<br />immediately.<br />- sudden loss of vision (frequency rare).<br />Other side effects have been reported:</p><p dir="ltr"><strong>Common</strong> (may affect up to 1 in 10 people)<br />- headache, back pain, muscle aches, pain in arms and legs, facial<br />flushing, nasal congestion, and indigestion.<br /><strong>Uncommon</strong> (may affect up to 1 in 100 people)<br />- dizziness, stomach ache, feeling sick, being sick (vomiting), reflux,<br />blurred vision, eye pain, difficulty in breathing, presence of blood in<br />urine, prolonged erection, pounding heartbeat sensation, a fast heart<br />rate, high blood pressure, low blood pressure, nose bleeds, ringing in<br />the ears, swelling of the hands, feet or ankles and feeling tired.<br /><strong>Rare</strong> (may affect up to 1 in 1,000 people)<br />- fainting, seizures and passing memory loss, swelling of the eyelids, red<br />eyes, sudden decrease or loss of hearing, hives (itchy red welts on the<br />surface of the skin), penile bleeding, presence of blood in semen and<br />increased sweating.<br />Heart attack and stroke have also been reported rarely in men taking<br />Tadafect. Most of these men had known heart problems before taking this<br />medicine.<br />Partial, temporary, or permanent decrease or loss of vision in one or both<br />eyes has been rarely reported.<br />Some additional rare side effects have been reported in men taking<br />Tadafect that were not seen in clinical trials. These include:<br />- migraine, swelling of the face, serious allergic reaction which causes<br />swelling of the face or throat, serious skin rashes, some disorders<br />affecting blood flow to the eyes, irregular heartbeats, angina and<br />sudden cardiac death.<br />The side effect dizziness has been reported more frequently in men over<br />75 years of age taking Tadafect. Diarrhoea has been reported more<br />frequently in men over 65 years of age taking Tadafect.<br /><strong>Reporting of side effects</strong></p><p dir="ltr"><strong>To report any side effect(s):</strong><br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Center (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton<br />and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is tadalafil. Each tablet contains 20 mg of tadalafil.<br />- The other ingredients are:<br />Tablet core: lactose monohydrate, Copovidone, Macrogol glycerol Hydroxy<br />Stearate, Silica, Colloidal Anhydrous, Cellulose, Microcrystalline, Croscarmellose<br />Sodium, Magnesium Stearate &amp; Purified water.<br />Film-coat: Opadry yellow 03K82780</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tadafect 20 mg is a Yellow colored, oval shaped, film-coated tablet
debossed with ‘20’ on one side and ‘TL’ on other side.
Tadafect 20 mg is available in blister packs containing 8 tablets
(4's blister x2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Manufacturing Site:<br />Aurobindo Pharma Limited,<br />Unit-VII (SEZ), TSIIC, Plot No. S1,<br />Survey Nos: 411/P, 425/P, 434/P, 435/P &amp; 458/P,<br />Green Industrial Park,<br />Polepally Village, Jedcherla Mandal,<br />Mahaboobnagar District, Telangana State, India.<br />Marketing Authorization Holder:<br />Aurobindo Pharma Saudi Arabia Limited,<br />Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2022, version number is 00.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي تادافكت على المادة الفعالة تادالافيل، والتي تنتمي لمجموعة من الأدوية تسمى مثبطات إنزيم فوسفوداي<br />إستيراز من النوع الخامس.<br />تادافكت هو علاج للرجال البالغين الذين يعانوا من خلل بالانتصاب، ويحدث هذا عند عجز الرجل في الحصول<br />على أو الاحتفاظ بقضيب منتصب صلب صالح للممارسة الجنسية. يُحسن تادافكت قابلية الحصول على قضيب<br />منتصب صلب صالح للممارسة الجنسية بصورة ملحوظة.<br />يحتوي تادافكت على المادة الفعالة تادالافيل، والتي تنتمي لمجموعة من الأدوية تسمى مثبطات إنزيم فوسفوداي<br />إستيراز من النوع الخامس. عقب التحفيز الجنسي، يعمل تادافكت عن طريق المساعدة على ارتخاء الأوعية<br />الدموية بقضيبك، سامحًا بتدفق الدم لقضيبك، مؤديًا إلى تحسن القدرة على الانتصاب. لن يساعدك تادافكت إذا<br />لم تكن تعاني من خلل الانتصاب.<br />يجب عليك ملاحظة أن تادافكت لا يعمل في غياب التحفيز الجنسي. ستحتاج أن تنغمس وشريكك في المداعبة،<br />تمامًا كما لو كنت لا تأخذ دواءً لخلل الانتصاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تأخذ تادافكت إن كنت:</strong><br />.) &minus; تمتلك حساسية تجاه تادالافيل أو أي من المكونات الأخرى للدواء )مذكورة في قسم 6<br />&minus; تأخذ أي شكل لمانحات النترات العضوية أو أكسيد النيتريك مثل نترات الأميل. هذه مجموعة من الأدوية<br />)&quot;نترات&quot;( تستخدم لعلاج الذبحة الصدرية )&quot;آلام الصدر&quot;(. يُزيد تادافكت من تأثير هذه الأدوية. أخبر<br />طبيبك في حالة أخذك لأي صورة للنترات أو إن لم تكن متأكدًا.<br />&minus; تعاني من مرض قلبي خطير، أو أصبت حديثًا بأزمة قلبية خلال ال 90 يومًا الأخيرة.<br />&minus; أصبت مؤخرًا بسكتة دماغية خلال ال 6 شهور الأخيرة.<br />&minus; تعاني من انخفاض ضغط الدم أو ضغط دم مرتفع غير مُتحكم فيه.<br />وهي حالة تسمي ،)NAION( &minus; فقدت بصرك نتيجة اعتلال عصبي بصري إقفاري أمامي غير شرياني<br />ب &ldquo;سكتة العين‟.<br />&minus; تأخذ ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الشرايين الرئوية )أي ارتفاع ضغط الدم<br />بالرئتين(، وارتفاع ضغط الدم الرئوي نتيجة الانصمام الخثاري المزمن )أي ارتفاع ضغط الدم بالرئتين<br />مثل )PDE الناتج عن الجلطات الدموية(. تُزيد مثبطات إنزيم فوسفوداي إستيراز من النوع الخامس ) 5<br />تادافكت من التأثير الخافض للضغط المصاحب لهذا الدواء. اعلم طبيبك إن كنت تأخذ ريوسيجوات أو إن<br />كنت غير متأكد.</p><p><strong>التحذيرات والاحتياطات</strong><br />تحدث مع طبيبك قبل أخذ تادافكت.<br />كن على علم بأن النشاط الجنسي قد يحمل خطرًا لمرضى القلب، وذلك لأنه يضع عبئًا زائدًا على قلبك. إن كنت<br />تعاني من مشاكل بالقلب، عليك إعلام طبيبك.<br />قبل أخذ الأقراص، اعلم طبيبك إن كنت تعاني من:<br />&minus; أنيميا خلايا الدم المنجلية )شذوذ بخلايا الدم الحمراء(.<br />&minus; الورم النخاعي المتعدد )سرطان نخاع العظام(.<br />&minus; ابيضاض الدم )سرطان خلايا الدم(.<br />&minus; أي تشوه بالقضيب.<br />&minus; مشاكل كبدية خطيرة<br />&minus; مشاكل كلوية خطيرة.<br />غير معلوم إن كان تادافكت فعا لدي المرضى الذين أجروا:<br />&minus; جراحة بالحوض<br />&minus; إزالة لغدة البروستاتا أو جزء منها، والذي اشتمل على قطع أعصاب البروستاتا )استئصال البروستاتا<br />الجذري غير العصبي(.<br />توقف عن أخذ تادافكت في حالة معاناتك من ضعف أو فقد البصر المفاجئ، واعلم طبيبك على الفور.<br />لوحظ ضعف أو فقد السمع المفاجئ لدي بعض المرضى الذين يأخذون تادالافيل، بالرغم من عدم معرفة ما إذا<br />كان هذا الحدث مرتبط بشكل مباشر بتادالافيل. توقف عن أخذ تادافكت في حالة معاناتك من ضعف أو فقد السمع<br />المفاجئ، واعلم طبيبك على الفور.<br />تادافكت غير مخصص للاستخدام من قبل النساء.</p><p><strong>الأطفال والمراهقون</strong><br />تادافكت غير مخصص للاستخدام من قبل الأطفال والمراهقين تحت سن 18 عام.<br />الأدوية الأخرى وتادافكت<br />اعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي دواء آخر.<br />لا تأخذ تادافكت في حالة أخذك للنترات.<br />قد تتأثر بعض الادوية بتادافكت، أو قد تؤثر على جودة عمل تادافكت. اعلم طبيبك أو الصيدلي إن كنت تأخذ:<br />&minus; موانع ألفا )تستخدم لعلاج أعراض ارتفاع ضغط الدم أو الأعراض البولية المصاحبة لتضخم البروستاتا<br />الحميد(.<br />&minus; أدوية أخرى لعلاج ارتفاع ضغط الدم.<br />&minus; ريوسيجوات.<br />&minus; مثبط لانزيم 5-ألفا ريداكتاز )يستخدم لعلاج تضخم البروستاتا الحميد(.<br />&minus; أدوية مثل أقراص كيتوكونازول )لعلاج العدوات الفطرية(، ومثبطات إنزيم البروتياز لعلاج متلازمة<br />.)HIV( نقص المناعة المكتسبة )الإيدز( أو عدوى فيروس نقص المناعة البشري<br />&minus; فينوباربيتول وفينايتوين وكاربامازيبين )أدوية مضادة للتشنجات(.<br />&minus; ريفامبيسين أو إيريثرومايسين أو كلاريثروميسين أو إيتراكونازول.<br />&minus; علاجات أخرى لخلل الانتصاب.<br /><strong>تادافكت مع المشروبات والكحول</strong><br />توجد معلومات حول تأثير الكحول بقسم 3. قد يؤثر عصير الجريب فروت على كفاءة عمل تادافكت، ويجب<br />أخذه بحذر. تحدث مع طبيبك للحصول على معلومات إضافية.<br /><strong>الخصوبة</strong><br />أظهرت الكلاب انخفاضًا بتطور الحيوانات المنوية بالخصيتين عند علاجهم. ظهر نقص بالمني عند بعض<br />الرجال، ولكن من غير المحتمل أن يؤدي هذا الحدث لفقد الخصوبة.<br /><strong>القيادة واستخدام الآلات</strong><br />عانى بعض الرجال من الدوخة عند أخذهم لتادافكت خلال الدراسات الإكلينيكية. تحقق جيدًا من كيفية استجابتك<br />للأقراص قبل القيادة أو استخدام الآلات.<br /><strong>يحتوي تادافكت على اللاكتوز:</strong><br />إن كنت تعاني من عدم التحمل لبعض السكريات، تواصل مع طبيبك قبل أخذ هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء بالضبط كما وصف طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.<br />يستخدم تادافكت أقراص فمويًا لدي الرجال فقط. ابتلع القرص كام مع بعض الماء. يمكن أخذ الأقراص مع<br />الطعام أو بدونه.<br /><strong>الجرعة المبدئية الموصي بها </strong>هي قرص واحد 10 مجم تادالافيل قبل الممارسة الجنسية، ومع ذلك، يمكنك<br />أخذ جرعة قدرها قرص واحد 20 مجم إذا قرر طبيبك أن جرعة 10 مجم الموصي بها شديدة الضعف.<br />يمكنك أخذ قرص تادافكت قبل الممارسة الجنسية ب 30 دقيقة على الأقل.<br />قد يظل تادافكت فعا حتى 36 ساعة بعد تناول القرص.<br />لا تأخذ تادافكت أكثر من مرة واحدة يوميًا. تادافكت 20 مجم مخصص للاستخدام قبل النشاط الجنسي المتوقع،<br />ولا يوصى به للاستخدام اليومي المستمر.<br />من المهم معرفة أن تادافكت لا يعمل في غياب التحفيز الجنسي. يجب أن تنغمس وشريكك في المداعبة،<br />تمامًا كما لو كنت لا تأخذ دواءً لخلل الانتصاب.<br />قد يخفض تناول الكحول من قدرتك في الحصول على انتصاب، كما قد يخفض من ضغط دمك بصورة<br />مؤقتة. إن كنت تتناول تادافكت أو تخطط لتناوله، تفادى الإفراط في شرب الكحول )مستوى كحول بالدم&nbsp;0.08 أو أكثر(، فقد يؤدي هذا إلى زيادة خطر الشعور بالدوخة عند الوقوف.<br /><strong>إذا اخذت تادافكت أكثر مما يجب</strong><br />&nbsp;تواصل مع طبيبك. قد تعاني من الآثار الجانبية المذكورة بقسم 4<br />إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء، أسئل طبيبك أو الصيدلي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم حدوثها لدي جميع الأشخاص. هذا الآثار<br />ذات طبيعة بسيطة إلى متوسطة في المعتاد.<br /><strong>إذا كنت تعاني من أي من الآثار الجانبية التالية، توقف عن استخدام الدواء، واطلب المساعدة الطبية فورًا:<br />&minus; تفاعلات التحسس والتي تتضمن الطفح (غير شائع التكرارية).</strong><br />&minus; آلام الصدر &ndash; لا تستخدم النترات، ولكن اطلب المساعدة الطبية الفورية )غير شائع التكرارية(.<br />&minus; قساح، وهو حدوث انتصاب مستمر ومؤلم في بعض الأحيان بعد أخذ تادافكت )نادر التكرارية(. إذا حدث<br />لك مثل هذا الانتصاب، والذي يستمر لأكثر من 4 ساعات، يجب عليك التواصل مع طبيبك على الفور.<br />&minus; الفقد المفاجئ للبصر )نادر التكرارية(.<br />الآثار الجانبية الأخرى التي تم الإبلاغ عنها:<br /><strong>(شائعة )قد تؤثر على 1 لكل 10 أشخاص</strong><br />&minus; الصداع، وآلام الظهر، وآلام العضلات، وآلام الذراعين والساقين، وتورم الوجه، واحتقان الأنف، وعسر<br />الهضم.</p><p dir="ltr"><strong>غير شائعة )قد تؤثر على 1 لكل 100 شخص)</strong><br />&minus; الدوخة، وآلام المعدة، والشعور بالإعياء، والإعياء )قيء(، والارتجاع، وعدم وضوح الرؤية، وآلام<br />العين، وصعوبة التنفس، وجود دم بالبول، والانتصاب المستمر، الشعور بنبض القلب غير المنتظم،<br />وسرعة نبض القلب، وارتفاع ضغط الدم، وانخفاض ضغط الدم، ونزيف الأنف، ورنين بالأذنين، وتورم<br />اليدين أو القدمين أو الكاحلين، والشعور بالإرهاق.<br /><strong>نادرة )</strong> قد تؤثر على 1 لكل 1000 شخص<strong>)</strong><br />&minus; الإغماء والنوبات وفقد الذاكرة وتورم الجفون واحمرار العينين وضعف أو فقد السمع المفاجئ والشرى<br />)ثنيات حمراء تسبب الحكة على سطح الجلد( ونزيف القضيب ووجود دم بالسائل المنوي وزيادة التعرق.<br />أُبلغ أيضًا عن أزمات قلبية وسكتات دماغية بصورة نادرة لدي الرجال المتعاطين لتادافكت، لكن معظم هؤلاء<br />الرجال كانت لديهم مشاكل معروفة بالقلب قبل أخذ هذا الدواء.<br />أُبلغ عن ضعف أو فقدان جزئي أو مؤقت أو دائم للبصر بإحدى العينين أو كلتاهما بصورة نادرة.<br />أُبلغ عن بعض الآثار الجانبية الإضافية والنادرة لدي الرجال الذين يأخذون تادافكت، والتي لم تظهر بالتجارب<br />الإكلينيكية، هذه الآثار الجانبية تتضمن:<br />&minus; الصداع النصفي وتورم الوجه وتفاعلات تحسسية خطيرة تتسبب في تورم الوجه أو الحلق وطفح جلدي<br />خطير وبعض الاضطرابات المؤثرة على تدفق الدم للعينين ونبض القلب غير المنتظم والذبحة الصدرية<br />والموت القلبي المفاجئ.<br />أُبلغ عن أثر الدوخة الجانبي بصورة أكثر تكرارية لدي الرجال الأكبر من 75 عامًا، والذين يأخذون تادافكت.<br />أُبلغ عن الإسهال بصورة أكثر تكرارية لدي الرجال الأكبر من 65 عامًا، والذين يأخذون تادافكت.<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />للإبلاغ عن أي آثار جانبية:<br />&nbsp;المملكة العربية السعودية<br />(NPC) - مركز اليقظة الدوائية الوطني<br />19999 :(SFDA) مركز اتصال الهيئة العامة للغذاء والدواء<br />npc.drug@sfda.gov.sa : &bull; البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابق هذا الدواء بعيدا عن نظر ومتناول الأطفال.<br />يشير تاريخ .&rdquo;EXP&ldquo; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العبوة والشريط بعد<br />انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.<br />يُحفظ تحت 30 درجة مئوية.<br />لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. أسال الصيدلي عن كيفية التخلص<br />من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مما يتكون تادافكت<br />المادة الفعالة هي تادالافيل. يحتوي كل قرص على 20 مجم من تادالافيل.<br />&minus; المكونات الأخرى هي:<br />محتوى القرص: لاكتوز أحادي الماء، كوبوفيدون، ماكروجول جليسرول هيدروكسي ستيرات، سيليكا غروية<br />لا مائية، سيليولوز دقيق التبلور، كروسكارميلوز صوديوم، ستيرات الماغنسيوم، ماء منقى<br />03K محتوى الغلاف: أوبادريل اصفر 82780</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو تادافكت ومحتويات العبوة<br />على الجانب &rdquo;TL &rdquo; تادافكت 20 مجم هو قرص بيضاوي مغلف ذو لون أصفر، محفور على أحد جانبيه &quot; 20 &quot;، و<br />الآخر.<br />&nbsp;تادافكت 20 مجم متوفر في 8 فجوات(شريط 4 2x &nbsp;فجوات)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>موقع التصنيع:<br />أوروبيندو فارما المحدودة،<br />،S المنطقة الاقتصادية الخاصة(، شركة البنية التحتية الصناعية بولاية تيلانجانا، قطعة رقم 1 ( VII- الوحدة<br />P/425 ،P/ مسح رقم: 411<br />الحديقة الصناعية الخضراء، قرية بوليبالي، منطقة جيدشيرلا،<br />حي ماهابوباجار، ولاية تيلانجانا، الهند.<br />حامل ترخيص التسويق:<br />أوروبيندو فارما السعودية المحدودة،<br />جدة، المملكة العربیة السعودیة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة لآخر مرة في: 2022/09
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                (TRADE) NAME OF PRODUCT : Tadafect
STRENGTH : 20 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
QUALITATIVE AND QUANTITATIVE COMPOSITIONS:
Tadalafil Tablets 20 mg
Each film-coated tablet contains 20 mg of Tadalafil Ph. Eur.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadalafil Tablets 20 mg: Yellow colored, oval shaped, film-coated tablets debossed with
‘20’ on one side and ‘TL’ on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment of erectile dysfunction in adult males.<br />In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual<br />stimulation is required.<br />Tadalafil is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Erectile dysfunction in adult men<br />In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and<br />with or without food. In those patients in whom tadalafil 10 mg does not produce an<br />adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual<br />activity.<br />The maximum dose frequency is once per day.<br />Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not<br />recommended for continuous daily use.</p><p dir="ltr">Special Populations<br />Elderly Men<br />Dose adjustments are not required in elderly patients.<br />Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For<br />patients with severe renal impairment, 10 mg is the maximum recommended dose.<br />Once-a-day dosing of tadalafil is not recommended in patients with severe renal impairment.<br />Men with Hepatic Impairment<br />The recommended dose of tadalafil is 10 mg taken prior to anticipated sexual activity and<br />with or without food. There is limited clinical data on the safety of tadalafil in patients with<br />severe hepatic impairment (Child-Pugh Class C); if prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician.<br />There are no available data about the administration of doses higher than 10 mg of tadalafil<br />to patients with hepatic impairment. Once-a-day dosing has not been evaluated in patients<br />with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation<br />should be undertaken by the prescribing physician<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients.<br />Paediatric population<br />There is no relevant use of Tadalafil in the paediatric population with regard to the treatment<br />of erectile dysfunction.<br />Method of administration<br />Tadalafil for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is
thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP
pathway.
Therefore, administration of Tadalafil to patients who are using any form of organic nitrate is
contraindicated.
Tadalafil must not be used in men with cardiac disease for whom sexual activity is
inadvisable.
Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting
cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical
trials and the use of tadalafil is therefore contraindicated:
• Patients with myocardial infarction within the last 90 days.
• Patients with unstable angina or angina occurring during sexual intercourse.
• Patients with New York Heart Association class 2 or greater heart failure in the last 6
months.
• Patients with uncontrolled arrhythmias, hypotension (<90/50mmHg), or uncontrolled
hypertension.
• Patients with a stroke within the last 6 months.
Tadalafil is contraindicated in patients who have loss of vision in one eye because of nonarteritic
anterior ischaemic optic neuropathy (NAION), regardless of whether this episode
was in connection or not with previous PDE5 inhibitor exposure.
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase
stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic
hypotension
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Before treatment with Tadalafil<br />A medical history and physical examination should be undertaken to diagnose erectile<br />dysfunction or benign prostatic hyperplasia and determine potential underlying causes,<br />before pharmacological treatment is considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the<br />cardiovascular status of their patients, since there is a degree of cardiac risk associated with<br />sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases<br />in blood pressure, and as such potentiates the hypotensive effect of nitrates.<br />The evaluation of erectile dysfunction should include a determination of potential underlying<br />causes and the identification of appropriate treatment following an appropriate medical<br />assessment. It is not known if tadalafil is effective in patients who have undergone pelvic</p><p dir="ltr">surgery or radical non-nerve-sparing prostatectomy.<br />Cardiovascular<br />Serious cardiovascular events, including myocardial infarction, sudden cardiac death,<br />unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest<br />pain, palpitations and tachycardia may occur in most of the patients who had preexisting<br />cardiovascular risk factors. However, it is not possible to definitively determine whether<br />these events are related directly to these risk factors, to tadalafil, to sexual activity, or to a<br />combination of these or other factors.<br />In patients who are taking alpha1 blockers, concomitant administration of tadalafil may lead<br />to symptomatic hypotension in some patients. The combination of tadalafil and doxazosin is<br />not recommended.<br />Vision<br />Visual defects and cases of NAION may occur in connection with the intake of Tadalafil and<br />other PDE5 inhibitors. Analyses of observational data suggest an increased risk of acute<br />NAION in men with erectile dysfunction following exposure to tadalafil or other PDE5<br />inhibitors. As this may be relevant for all patients exposed to tadalafil, the patient should be<br />advised that in case of sudden visual defect, he should stop taking Tadalafil and consult a<br />physician immediately.<br />Hepatic impairment<br />There is limited clinical data on the safety of single-dose administration of Tadalafil in<br />patients with severe hepatic insufficiency (Child-Pugh Class C). If Tadalafil is prescribed, a<br />careful individual benefit/risk evaluation should be undertaken by the prescribing physician</p><p dir="ltr">Priapism and anatomical deformation of the penis<br />Patients who experience erections lasting 4 hours or more should be instructed to seek<br />immediate medical assistance. If priapism is not treated immediately penile tissue damage<br />and permanent loss of potency may result.<br />Tadalafil, should be used with caution in patients with anatomical deformation of the penis<br />(such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have<br />conditions which may predispose them to priapism (such as sickle cell anaemia, multiple<br />myeloma, or leukaemia).<br />Use with CYP3A4 inhibitors<br />Caution should be exercised when prescribing Tadalafil to patients using potent CYP3A4<br />inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased<br />tadalafil exposure (AUC) has been observed if the medicinal products are combined.<br />Tadalafil and other treatments for erectile dysfunction<br />The safety and efficacy of combinations of Tadalafil and other PDE5 inhibitors or other<br />treatments for erectile dysfunction have not been studied. The patients should be informed<br />not to take Tadalafil in such combinations.</p><p dir="ltr">Excipients<br />Lactose<br />Tadalafil tablets contain lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take<br />this medicinal product.<br />Sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />&#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below.<br />With regard to those interaction studies where only the 10 mg tadalafil dose was used,<br />clinically relevant interactions at higher doses cannot be completely ruled out.<br />Effects of Other Substances on Tadalafil<br />Cytochrome P450 inhibitors<br />Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4,<br />ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by<br />15%, relative to the AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily)<br />increased tadalafil (20mg) exposure (AUC) 4-foId and Cmax by 22%. Ritonavir, a protease<br />inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and<br />CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fo1d with no change in Cmax. Other<br />protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,<br />clarithromycin, itraconazole, and grapefruit Juice, should be co-administered with caution, as<br />they would be expected to increase plasma concentrations of tadalafil. Consequently, the<br />incidence of the adverse reactions might be increased.</p><p dir="ltr">Transporters<br />The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not<br />known. Therefore, there is the potential of drug interactions mediated by inhibition of<br />transporters.<br />Cytochrome P450 inducers<br />A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values<br />for tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy<br />of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4,<br />such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma<br />concentrations of tadalafil.<br />Effects of Tadalafil on Other Medicinal Products<br />Nitrates<br />Tadalafil (5 mg, 10 mg and 20 mg) may augment the hypotensive effects of nitrates.<br />Therefore, administration of tadalafil to patients who are using any form of organic nitrate is<br />contraindicated. In a patient prescribed any dose of tadalafil (2.5 mg &ndash; 20 mg), where nitrate<br />administration is deemed medically necessary in a life-threatening situation, at least 48 hours<br />should have elapsed after the last dose of tadalafil before nitrate administration is considered.<br />In such circumstances, nitrates should only be administered under close medical supervision<br />with appropriate haemodynamic monitoring.<br />Anti-hypertensives (including calcium channel blockers)<br />The co-administration of doxazosin (4 and 8mg daily) and tadalafil (5mg daily dose and<br />20mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a<br />significant manner. This effect lasts at least twelve hours and may be symptomatic, including<br />syncope. Therefore, this combination is not recommended.</p><p dir="ltr">In interaction studies performed in a limited number of healthy volunteers, these effects were<br />not reported with alfuzosinor tamsulosin. However, caution should be exercised when using<br />tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments<br />should be initiated at minimal dosage and progressively adjusted.<br />In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive<br />effects of antihypertensive medicinal products was examined. Major classes of<br />antihypertensive medicinal products were studied, including calcium channel blockers<br />(amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic<br />receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II<br />receptor blockers (various types and doses, alone or in combination with thiazides, calcium<br />channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg except for studies<br />with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had<br />no clinically significant interaction with any of these classes. In another clinical<br />pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of<br />antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-bloodpressure<br />changes appeared to relate to the degree of blood-pressure control. In this regard,</p><p dir="ltr">study subjects whose blood pressure was well controlled, the reduction was minimal and<br />similar to that seen in healthy subjects. In study subjects whose blood pressure was not<br />controlled, the reduction was greater although this reduction was not associated with<br />hypotensive symptoms in the majority of subjects. In patients receiving concomitant<br />antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease,<br />which (with the exception of alpha blockers -see above-) is, in general, minor and not likely<br />to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in<br />adverse events in patients taking tadalafil with or without antihypertensive medicinal<br />products. However, appropriate clinical advice should be given to patients regarding a<br />possible decrease in blood pressure when they are treated with antihypertensive medicinal<br />products.<br />Riociguat<br />Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5<br />inhibitors were combined with riociguat. Riociguat has been shown to augment the<br />hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect<br />of the combination in the population studied. Concomitant use of riociguat with PDE5<br />inhibitors, including tadalafil, is contraindicated</p><p dir="ltr">5- alpha reductase inhibitors<br />When tadalafil 5 mg coadministered with finasteride 5 mg to placebo plus finasteride 5 mg in<br />the relief of BPH symptoms, no new adverse reactions were identified. However, as a formal<br />drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors<br />(5-ARIs) has not been performed, caution should be exercised when tadalafil is coadministered<br />with 5-ARIs.<br />CYP1A2 substrates (e.g. theophylline)<br />When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase<br />inhibitor), there will be no pharmacokinetic interaction. The only pharmacodynamic effect<br />was a small (3.5 bpm) increase in heart rate. Although this effect is minor and was of no<br />clinical significance, it should be considered when co-administering these medicinal<br />products.<br />Ethinylestradiol and terbutaline<br />Tadalafil has been demonstrated to produce an increase in the oral bioavailability of<br />ethinylestradiol; a similar increase may be expected with oral administration of terbutaline,<br />although the clinical consequence of this is uncertain.<br />Alcohol<br />Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by<br />co-administration with tadalafil (10mg or 20mg). In addition, no changes in tadalafil<br />concentrations were seen 3 hours after co-administration with alcohol. Alcohol was<br />administered in a manner to maximise the rate of alcohol absorption (overnight fast with no<br />food until 2 hours alter alcohol). Tadalafil (20mg) did not augment the mean blood pressure<br />decrease produced by alcohol (0.7g/kg or approximately 180 ml of 40% alcohol [vodka] in<br />an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were<br />observed. When tadalafil was administered with lower doses of alcohol (0.6g/kg),<br />hypotension was not observed and dizziness occurred with similar frequency to alcohol<br />alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10mg).</p><p dir="ltr">Cytochrome P450 metabolised medicinal products<br />Tadalafil is not expected to cause clinically significant inhibition or induction of the<br />clearance of medicinal products metabolised by CYP450 isoforms. Studies have confirmed<br />that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2,<br />CYP2D6, CYP2E1, CYP2C9 and CYP2C19.<br />CYP2C9 substrates (e.g. R-warfarin)<br />Tadalafil (10mg and 20mg) had no clinically significant effect on exposure (AUC) to Swarfarin<br />or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin<br />time induced by warfarin.<br />Aspirin<br />Tadalafil (10mg and 20mg) did not potentiate the increase in bleeding time caused by<br />acetylsalicylic acid.<br />Antidiabetic medicinal products<br />Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Tadalafil is not indicated for use by women.<br />Pregnancy<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not<br />indicate direct or indirect harmful effects with respect to pregnancy embryonal/foetal<br />development, parturition or postnatal development. As a precautionary measure, it is<br />preferable to avoid the use of Tadalafil during pregnancy.<br />Breastfeeding<br />Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil<br />in milk. A risk to the suckling child cannot be excluded. Tadalafil should not be used during<br />breast feeding.<br />Fertility<br />Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical<br />studies suggest that this effect is unlikely in humans, although a decrease in sperm<br />concentration was seen in some men</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Tadalafil has negligible influence on the ability to drive or use machines. Although the<br />frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar,<br />patients should be aware of how they react to tadalafil, before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Summary of the safety profile<br />The most commonly reported adverse reactions in patients taking Tadalafil for the treatment<br />of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain<br />and myalgia, in which the incidences increase with increasing dose of Tadalafil. The adverse<br />reactions reported were transient, and generally mild or moderate. The majority of headaches<br />reported with Tadalafil once-a-day dosing are experienced within the first 10 to 30 days of<br />starting treatment.<br />Tabulated summary of adverse reactions<br />The table below lists the adverse reactions observed from spontaneous reporting and in<br />placebo controlled clinical trials(comprising a total of 7116 patients on tadalafil and 3718<br />patients on placebo) for on-demand and once-a-day treatmentof erectile dysfunction and the<br />once-a- day treatment of benign prostatic hyperplasia.<br />Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon<br />(&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000) and Not known<br />(cannot be estimated from the available data).</p><p dir="ltr">Common (may affect up to 1 in 10 people)<br />- headache, back pain, muscle aches, pain in arms and legs, facial<br />flushing, nasal congestion, and indigestion.<br />Uncommon (may affect up to 1 in 100 people)<br />- dizziness, stomach ache, feeling sick, being sick (vomiting), reflux,<br />blurred vision, eye pain, difficulty in breathing, presence of blood in<br />urine, prolonged erection, pounding heartbeat sensation, a fast heart<br />rate, high blood pressure, low blood pressure, nose bleeds, ringing in<br />the ears, swelling of the hands, feet or ankles and feeling tired.<br />Rare (may affect up to 1 in 1,000 people)<br />- fainting, seizures and passing memory loss, swelling of the eyelids, red<br />eyes, sudden decrease or loss of hearing, hives (itchy red welts on the<br />surface of the skin), penile bleeding, presence of blood in semen and<br />increased sweating.<br />Heart attack and stroke have also been reported rarely in men taking<br />Tadafect. Most of these men had known heart problems before taking this<br />medicine.<br />Partial, temporary, or permanent decrease or loss of vision in one or both<br />eyes has been rarely reported.<br />Some additional rare side effects have been reported in men taking<br />Tadafect that were not seen in clinical trials. These include:<br />- migraine, swelling of the face, serious allergic reaction which causes<br />swelling of the face or throat, serious skin rashes, some disorders<br />affecting blood flow to the eyes, irregular heartbeats, angina and<br />sudden cardiac death.<br />The side effect dizziness has been reported more frequently in men over<br />75 years of age taking Tadafect. Diarrhoea has been reported more<br />frequently in men over 65 years of age taking Tadafect.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Single doses of up to 500 mg have been given to healthy subjects and multiple daily doses up<br />to 100 mg have been given to patients. Adverse events were similar to those seen at lower<br />doses. In cases of overdose, standard supportive measures should be adopted, as required.<br />Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC Code:<br />G04BE08.<br />Mechanism of action<br />Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-<br />specific phosphodiesterase type5 (PDE5). When sexual stimulation causes the local release<br />of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the<br />corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the<br />penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of<br />erectile dysfunction in the absence of sexual stimulation.<br />Pharmacodynamic effects<br />Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an<br />enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle,<br />skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent<br />on PDE5 than on other phosphor diesterases. Tadalafil is &gt; 10,000-foldmore potent for PDE5</p><p dir="ltr">than for PDE1, PDE2, and PDE4, enzymes which are found in the heart, brain, blood vessels,<br />liver, and other organs. Tadalafil is &gt; 10,000-fold more potent for PDE5 than for PDE3, an<br />enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is<br />important because PDE3 is an enzyme involved in cardiac contractility. Additionally,<br />tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is<br />found in the retina and is responsible for photo transduction. Tadalafil is also &gt; 10,000-fold<br />more potent for PDE5 than forPDE7 through PDE10.<br />Clinical efficacy and safety<br />Tadalafil administered to healthy subjects produced no significant difference compared to<br />placebo in supine systolic and diastolic blood pressure (mean maximal decrease of<br />1.6/0.8mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal<br />decrease of 0.2/4.6mmHg, respectively), and no significant change in heart rate.<br />In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination<br />(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is<br />consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical<br />studies, reports of changes in colour vision were rare (&lt;0.1%).<br />Three studies were conducted in men to assess the potential effect on spermatogenesis of<br />tadalafil 10mg (one 6-monthstudy) and 20mg (one 6-month and one 9-month study)<br />administered daily. In two of these studies decreases were observed in sperm count and<br />concentration related to tadalafil treatment of unlikely clinical relevance. These effects were<br />not associated with changes in other parameters, such as motility, morphology, and FSH.<br />Erectile dysfunction<br />Three clinical studies were conducted in 1054 patients in an at-home setting to define the<br />period of responsiveness to tadalafil on demand. Tadalafil demonstrated statistically<br />significant improvement in erectile function and the ability to have successful sexual<br />intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain<br />erections for successful intercourse compared to placebo as early as 16 minutes following<br />dosing.</p><p dir="ltr">In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile<br />dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile<br />function leading to a mean per-subject proportion of successful attempts in patients treated<br />with tadalafil 10 or 20 mg (flexible-dose, on demand) of 48% as compared to 17% with<br />placebo.<br />Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250<br />patients, including patients with erectile dysfunction of various severities (mild, moderate,<br />severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile<br />dysfunction of at least 1 year in duration. In the primary efficacy studies of general<br />populations, 81% of patients reported that tadalafil improved their erections as compared to<br />35% with placebo. Also, patients with erectile dysfunction in all severity categories reported<br />improved erections whilst taking tadalafil (86%, 83%, and 72% for mild, moderate, and<br />severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the primary<br />efficacy studies, 75% of intercourse attempts were successful in tadalafil- reated patients as<br />compared to 32% with placebo.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies in<br />all subsets of the paediatric population in the treatment of the erectile dysfunction. See<br />section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u><br />Tadalafil is readily absorbed after oral administration and the mean maximum observed<br />plasma concentration (Cmax) is achieved at a median time or 2 hours after dosing. Absolute<br />bioavailability of tadalafil following oral dosing has not been determined.<br />The rate and extent of absorption of tadalafil are not influenced by food, thus tadalafil may<br />be taken with or without food. The time of dosing (morning versus evening) had no clinically<br />relevant effects on the rate and extent of absorption.<br /><u>Distribution</u><br />The mean volume of distribution is approximately 63 litres, indicating that tadalafil is<br />distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to<br />proteins. Protein binding is not affected by impaired renal function.<br />Less than 0.0005 % of the administered dose appeared in the semen of healthy subjects.</p><p dir="ltr"><u>Elimination</u><br />The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy<br />subjects.<br />Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces<br />(approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of<br />the dose).<br />Linearity/non-linearity<br />Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over<br />a dose range of 2.5 to 20mg, exposure (AUC) increases proportionally with dose. Steadystate<br />plasma concentrations are attained within 5 days of once-daily dosing.<br />Pharmacokinetics determined with a population approach in patients with erectile<br />dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.<br />Special populations<br />Elderly<br />Healthy elderly subjects (65 years or over), had a lower oral clearance of tadalafil, resulting<br />in 25 % higher exposure(AUC) relative to healthy subjects aged 19 to 45 years. This effect of<br />age is not clinically significant and does not warrant a dose adjustment.<br />Renal insufficiency<br />In clinical pharmacology studies using single-dose tadalafil (up to 20 mg), tadalafil exposure<br />(AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min)<br />or moderate (creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with<br />end-stage renal disease on dialysis.In haemodialysis patients, Cmax was 41 %higher than that observed in healthy subjects.<br />Haemodialysis contributes negligibly to tadalafil elimination.<br />Hepatic insufficiency<br />Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-<br />Pugh Class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is<br />administered. There is limited clinical data on the safety of tadalafil in patients with severe<br />hepatic insufficiency (Child- Pugh Class C). If tadalafil is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician. There are no<br />available data about the administration of doses higher than 10mg of tadalafil to patients with<br />hepatic impairment.<br />Patients with diabetes<br />Tadalafil exposure (AUC) in patients with diabetes was approximately 19 % lower than the<br />AUC value for healthy subjects. This difference in exposure does not warrant a dose<br />adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data reveal no special hazard for humans based on conventional studies of<br />safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and<br />toxicity to reproduction.<br />There was no evidence of teratogenicity, embryo toxicity or foetotoxicity in rats or mice that<br />received up to 1000mg/kg/day tadalafil. In a rat prenatal and postnatal development study,<br />the no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated<br />free drug at this dose was approximately 18 times the human AUC at a 20 mg dose.<br />There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for<br />6 to 12 months at doses of25 mg/kg/day (resulting in at least a 3-fold greater exposure [range<br />3.7 &ndash; 18.6] than seen in humans given a single 20mg dose) and above, there was regression<br />of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some<br />dogs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Lactose monohydrate, Copovidone, Macrogol<br />glycerol Hydroxy Stearate, Silica colloidal anhydrous, Cellulose microcrystalline,<br />Croscarmellose sodium, Magnesium stearate and Purified water and Opadry yellow<br />03K82780.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30&deg;C. Protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Blister pack:<br />Tadalafil Tablets 20 mg: Blister of 8&rsquo;s (4&rsquo;s blister x 2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with<br />local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March, 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>